Mark M Archie, MD
Vascular Surgery · Bellflower
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 13 years
- Meharry Medical College School of Medicine, 2013
Offices
1 location · Bandb Medical Group Inc · 9 clinicians in this group
Looking this up.
Hospitals listed: Lac/Harbor-UCLA Med Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Archie’s office at (562) 888-8961 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lac/Harbor-UCLA Med CenterTorrance, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Los Angeles County Department of Health Services, which runs 4 hospitalsPatients rate it 2 of 5 · 61% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.4 (1.03 to 1.76), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.19 (3.89 to 8.48) · 636 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.418, Oct 2024 – Sep 2025
See every measure and the patient survey for Lac/Harbor-UCLA Med Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.4 (1.03 to 1.76) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.19 (3.89 to 8.48) · 636 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.418 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.72 (0.69 to 2.74) · 510 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 177.34 (124.5 to 230.19) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.3 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.6 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.8 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.6 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 15.3 · 73 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 1,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,023 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 3,035 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.25) · 189 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.6 to 3.72) · 621 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 16.15 (7.82 to 24.48) · 207 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.39 (3.47 to 11.31) · 207 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.66 (1.17 to 4.15) · 134 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.69 (0 to 1.46) · 2,400 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.138 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.458 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.312 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.093 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 113 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.1 · 190 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.6 · 134 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.2 · 122 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.4 · 162 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.4 (5 to 10.8) · 115 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.2 to 17.3) · 115 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 93 cases | None | Jul 2023 – Jun 2025 |
What patients said (1,594 patients answered, 15% of those asked)
| Cleanliness | 1 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 53% |
| Nurses "always" communicated well | 68% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 75% |
| "Always" quiet at night | 30% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 100% of their 16 Part D prescriptions in 2018. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2018 | 16 | 15 | 100% (16) | None | $439 |
| 2017 | 20 | 20 | 95% (19) | 0% | $124 |
| 2016 | 34 | 32 | 91% (31) | None | $376 |
| 2013 | 17 | None | 0% (0) | None | $2,602 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2017: 1 drug
| Hydrocodone-Acetaminophen | 14 | $79 | $6 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 22 | $213 | $10 |
Money from drug and device companies
$1,173 in 2025
| 2025 | 11 | 16 | None | $1,173 |
| 2024 | 12 | 23 | None | $2,217 |
| 2023 | 4 | 26 | None | $9,702 |
| 2022 | 5 | 22 | None | $1,278 |
| 2021 | 3 | 6 | None | $689 |
| 2020 | 3 | 7 | None | $258 |
| 2019 | 4 | 7 | None | $302 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| InspireMD | Cguard Prime Carotid Stent System | $271 | 2 payments
|
| Balt USA | Prestige Coil System | $225 | 3 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $173 | 1 payment
|
| W. L. Gore & Associates | Gore Excluder Thoracoabdominal Branch Endoprosthesis | $164 | 3 payments
|
| Bard Peripheral Vascular | Rotarexs 6 F X 135 Cm | $98 | 1 payment
|
| Medtronic | Endurant Iis | $61 | 1 payment
|
See all 16 published payments
| Balt USA | Meals · 2025-11-07 | Prestige Coil System | $104 |
| Cleerly | Meals · 2025-11-05 | Cleerly Ischemia | $56 |
| Bolton Medical | Meals · 2025-10-29 | Treo Abdominal Stent-Graft System | $25 |
| InspireMD | Meals · 2025-10-29 | Cguard Prime Carotid Stent System | $196 |
| W. L. Gore & Associates | Meals · 2025-09-19 | Gore Excluder Thoracoabdominal Branch Endoprosthesis | $28 |
| Medtronic | Meals · 2025-09-16 | Endurant Iis | $61 |
| InspireMD | Meals · 2025-09-16 | Cguard Prime Carotid Stent System | $75 |
| Shockwave Medical | Meals · 2025-08-28 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $173 |
| Bard Peripheral Vascular | Meals · 2025-08-12 | Rotarexs 6 F X 135 Cm | $98 |
| W. L. Gore & Associates | Meals · 2025-07-23 | Excluder Conformable Aaa Endoprosthesis With Active Control | $27 |
| Balt USA | Meals · 2025-05-20 | Prestige Coil System | $98 |
| Acera Surgical | Meals · 2025-05-15 | Restrata Wound Matrix | $27 |
| Laminate Medical Technologies | Meals · 2025-02-26 | Vasq | $21 |
| W. L. Gore & Associates | Meals · 2025-02-12 | Gore Excluder Thoracoabdominal Branch Endoprosthesis | $109 |
| Cagent Vascular | Meals · 2025-02-07 | Serrantor | $52 |
| Balt USA | Meals · 2025-01-23 | Prestige Coil System | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,217
| Balt USA | Prestige Coil System | $971 | 10 payments
|
| Abiomed | Impella | $312 | 1 payment
|
| Laminate Medical Technologies | Vasq External Support | $231 | 2 payments
|
| Edwards Lifesciences | Sapien 3 Ultra Resilia | $164 | 1 payment
|
| Inari Medical | Flowtriever Catheter, S | $162 | 1 payment
|
| Cordis US | S.M.A.R.T. Control | $133 | 1 payment
|
| Bolton Medical | Treo Abdominal Stent-Graft System | $123 | 2 payments
|
| Medtronic | In.Pact Admiral | $34 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $28 | 1 payment
|
| Ethicon US | Surgiflo Hemostatic Matrix | $25 | 1 payment
|
| Abbott Laboratories | Perclose Prostyle | $19 | 1 payment
|
| CVRx | Barostim Neo System | $13 | 1 payment
|
2023: $9,702
| Medtronic | Endurant Iis | $8,872 | 18 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $424 | 4 payments
|
| Silk Road Medical | Enroute Transcarotid Neuroprotection System | $391 | 3 payments
|
| Smith+Nephew | Collagenase Santyl | $14 | 1 payment
|
2022: $1,278
| Medtronic | Endurant Iis | $516 | 7 payments
|
| Philips Electronics North America | (6391) Nexcimer | $342 | 4 payments
|
| Silk Road Medical | Enroute Transcarotid Stent | $279 | 5 payments
|
| Abbott Laboratories | Supera | $120 | 5 payments
|
| Smith+Nephew | Collagenase Santyl | $20 | 1 payment
|
2021: $689
| Philips Electronics North America | (6371) Laser Cvx300 | $263 | 1 payment
|
| Medtronic | Hawkone | $246 | 2 payments
|
| Abbott Laboratories | Supera Peripheral Stent System | $181 | 3 payments
|
2020: $258
| Abbott Laboratories | Supera Peripheral Stent System | $182 | 5 payments
|
| Medtronic Vascular | Valiant Captivia | $44 | 1 payment
|
| Covidien LP | Surgipro | $32 | 1 payment
|
2019: $302
| Medtronic Vascular | Valiant Navion | $189 | 2 payments
|
| Maquet Cardiovascular U.S. Sales L.L.C. | Flixene | $61 | 2 payments
|
| Boston Scientific | General Thrombectomy | $32 | 2 payments
|
| Cardiovascular Systems | Peripheral Orbital Atherectomy System | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Inari Medical, Inc. · Promise III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia · 2024 | Their institution | $9,500 |
Professional record
- NPI
- 1033553383
- Trained
- Meharry Medical College School of Medicine, 2013 · 13 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2086S0129X (2086S0129X); Student in a training program (390200000X)
- Mailing address
- Po Box 411185, Boston, MA, 02241
- NPI first listed
- 2013-04-17
- NPI last updated
- 2025-05-28
- NPI record certified
- 2025-05-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 16506 Lakewood Blvd Ste 200, Bellflower, CA, 90706